Daniel Sutherlin
Affiliations: | 1998- | University of California, Berkeley, Berkeley, CA, United States |
Google:
"Daniel Sutherlin"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Sun S, Jia Q, Zenova AY, et al. (2018) Identification of selective acyl sulfonamide-cycloalkylether inhibitors of the voltage gated sodium channel (NaV) 1.7 with potent analgesic activity. Journal of Medicinal Chemistry |
| Chernov-Rogan T, Li T, Lu G, et al. (2018) Mechanism-specific assay design facilitates the discovery of Nav1.7-selective inhibitors. Proceedings of the National Academy of Sciences of the United States of America |
| Safina BS, Elliott RL, Forrest AK, et al. (2017) Design of Selective Benzoxazepin PI3Kδ Inhibitors Through Control of Dihedral Angles. Acs Medicinal Chemistry Letters. 8: 936-940 |
| Safina BS, Sweeney ZK, Li J, et al. (2013) Identification of GNE-293, a potent and selective PI3Kδ inhibitor: navigating in vitro genotoxicity while improving potency and selectivity. Bioorganic & Medicinal Chemistry Letters. 23: 4953-9 |
| Olivero AG, Heffron TP, Baumgardner M, et al. (2013) Abstract DDT02-01: Discovery of GDC-0032: A beta-sparing PI3K inhibitor active against PIK3CA mutant tumors. Cancer Research. 73 |
| Murray JM, Sweeney ZK, Chan BK, et al. (2012) Potent and highly selective benzimidazole inhibitors of PI3-kinase delta. Journal of Medicinal Chemistry. 55: 7686-95 |
| Sutherlin DP, Baker S, Bisconte A, et al. (2012) Potent and selective inhibitors of PI3Kδ: obtaining isoform selectivity from the affinity pocket and tryptophan shelf. Bioorganic & Medicinal Chemistry Letters. 22: 4296-302 |
| Safina BS, Baker S, Baumgardner M, et al. (2012) Discovery of novel PI3-kinase δ specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition. Journal of Medicinal Chemistry. 55: 5887-900 |
| Sutherlin DP, Bao L, Berry M, et al. (2011) Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. Journal of Medicinal Chemistry. 54: 7579-87 |
| Wolf BB, Quan C, Tran T, et al. (2008) On the edge of validation--cancer protease fibroblast activation protein. Mini Reviews in Medicinal Chemistry. 8: 719-27 |